A perspective on the women's healthy study: Aspirin prevents stroke but not MI in Women; Vitamin E has no effect on CV disease or cancer

Cleveland Clinic Journal of Medicine

Volumn 73, Issue 9, 2006, Pages 863-870

  Buring, Julie E ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Women's Health Study ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMATURIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; PEPTIC ULCER; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SKIN BRUISING; SMOKING; STATISTICAL SIGNIFICANCE; WOMEN'S HEALTH; CHEMOPROPHYLAXIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

AGED; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHEMOPREVENTION; FEMALE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; PLACEBOS; VITAMIN E;

EID: 33748643211     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.73.9.863     Document Type: Article

References (30)

1. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-1304.
2. Lee I-M, Cook NR Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer. The Women's Health Study: a randomized controlled trial. JAMA 2005; 294:56-65.
3. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135.
4. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296:313-316.
5. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagu!ation with warfarin and low-dose aspirin, in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1988; 351:233-241.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
7. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357:89-95 [Erratum, Lancet 2001; 357:1134].
8. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:161-172.
9. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002; 106:388-391.
10. Mosca L, Appel U, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004; 109:672-693.
11. Montgomery PR, Berger LG, Mitenko PA. Sitar DS. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther 1986; 39:571-576.
12. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523-534.
13. Rodondi N, Bauer DC. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am J Med 2004; 117:528-530.
14. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid: the HOT study. J Hypertens 2000; 18:629-642.
15. Meydani M. Vitamin E. Lancet 1995; 345:170-175.
16. Upston JM. Terentis AC, Stocker R. Tocopherol-mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 1999; 13:977-994.
17. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA. Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444-1449.
18. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WE. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-1456.
19. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334:1156-1162.
20. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53(suppl):326S-334S.
21. Patterson RE, White E, Kristal AR, Neuhouser ML, Potter JD. Vitamin supplements and cancer risk: the epidemiologic evidence. Cancer Causes Control 1997; 8:786-802.
22. Ritenbaugh C, Streit K, Helfand M. Summary of evidence from randomized controlled trials: routine vitamin supplementation to prevent cancer. Rockville, Md: Agency for Healthcare Research and Quality. www.ahrq.gov/ clinic/3rduspstf/vitamins/vitasum.htm. Accessed Aug 14, 2006.
23. Atkins D., Shetty P, Update of the evidence from randomized controlled trials, 1999-2002: routine vitamin supplementation to prevent cancer. Rockville, Md: Agency for Healthcare Research and Quality. www.ahrq.gov/ clinic/3rduspstf/vitamins/vitupdate.htm. Accessed Aug 14,2006.
24. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma PA. Appel LI, Gualler E. Meta-analysis: high-dosage vitamin E supplementation may increase alkause mortality. Ann Intern Med 2005; 142:37-46.
25. Sanderson S, Emery J, Baglin T, Kinmonth A-L, Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142:370-380.
26. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
27. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86 [Erratum, BMJ 2002; 324:141].
28. Ridker PM, Hennekens CH, Tofler GH, Lipinska I. Buring JE. Anti-platelet effects of 100 mg alternate day oral aspirin: a randomized, double-blind, placebo-controlled trial of regular and enteric coated formulations in men and women. J Cardiovasc Risk 1996, 3:209-212.
29. Hercberg S, Galan P, Preziosi P, et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164:2335-2342 [Erratum Arch Intern Med 2005; 165:286].
30. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338-1347.